Clinical Assessment of Late Health Outcomes in Survivors of Wilms Tumor
Topic overview
Long-term study of 280 Wilms tumor survivors reveals threefold higher burden of chronic health conditions compared to controls, with significant endocrine, cardiovascular, and pulmonary complications decades after treatment. Findings emphasize need for individualized surveillance and clinical management in this survivor population.
Key takeaways
- Wilms tumor survivors have 3x more chronic health conditions than matched controls by age 40, averaging 7.5 grade 2-4 conditions vs 2.3.
- Most prevalent late effects: endocrine dysfunction (54%), cardiovascular disease (26%), pulmonary complications (18%), and secondary cancers (8%).
- Survivors show significant neurocognitive impairment and physical function deficits requiring targeted rehabilitation and support.
- Doxorubicin (67% received) and radiation therapy (59% abdominal, 25% chest) drive much of the late toxicity burden.
- Individualized surveillance protocols based on treatment exposures are essential for early detection and management of late effects.
Comments